compare to NEU, Rett Syndrome approval, share price close to doubled in around a week.
I think the moral of the story is, no one knows the true outcome until it does happen.
but as we see with NEU and others, and as you mention really the true test is going to be sales data. There might be some good catalysts like sales agreements etc between hopeful FDA approval and sales data but that’s really when the rubber hits the road for investors.
Ann: Final Sofdra Labelling Discussions with FDA, page-73
-
- There are more pages in this discussion • 210 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.3¢ |
Change
-0.003(0.70%) |
Mkt cap ! $628.9M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.5¢ | 34.5¢ | $694.8K | 1.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 264097 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 239596 | 7 |
View Market Depth
| Last trade - 12.08pm 28/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |